Good Science but Poor Management (Favoritism and Nepotism is Rampant) - Senior Scientist bei Merck: Mitarbeiterbewertung

2.0
4. Nov. 2018
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Good science, lot of projects to work on and promising portfolio.

Kontras

Many re-orgs this year. Good people at management level are leaving and people with little or no management skills are given their positions. Favoritism and Nepotism is very rampant - can be seen in who they hire, who is given promotion and who gets the "most visible" projects. Lack of innovation and some projects seem redundant with unnecessary more stress on resources.

Mehr Bewertungen zu Merck entdecken

5.0
3. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

End of the year shutdown which includes paid time off

Kontras

The con for me at the time was that I had to relocate which wasn’t possible

4.0
2. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Over my tenure, I had the opportunity to work alongside highly talented and mission-driven colleagues dedicated to improving patient outcomes. The organization provided exposure to cross-functional collaboration, leadership development opportunities, and meaningful work supporting healthcare providers, patients, and community stakeholders. I appreciated the company's commitment to innovation, professional growth, and serving patients through scientific advancement.

Kontras

Like many large organizations, priorities and organizational structures evolved over time, which occasionally created uncertainty and changes in responsibilities. Decision-making processes could sometimes be complex due to the size of the organization, and navigating multiple layers of stakeholders occasionally impacted speed and execution.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle